These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 25771376)
1. Alternative method to determine Specific Activity of (177)Lu by HPLC. Breeman WA; de Zanger RM; Chan HS; de Blois E Curr Radiopharm; 2015; 8(2):119-22. PubMed ID: 25771376 [TBL] [Abstract][Full Text] [Related]
3. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course. Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852 [TBL] [Abstract][Full Text] [Related]
4. The development and validation of a high performance liquid chromatography method to determine the radiochemical purity of [ van Andel L; Aalbersberg EA; Geluk-Jonker MM; Stokkel MPM; Beijnen JH; Hendrikx JJMA J Chromatogr B Analyt Technol Biomed Life Sci; 2021 May; 1171():122605. PubMed ID: 33740691 [TBL] [Abstract][Full Text] [Related]
5. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation. Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165 [TBL] [Abstract][Full Text] [Related]
7. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Breeman WA; De Jong M; Visser TJ; Erion JL; Krenning EP Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):917-20. PubMed ID: 12677301 [TBL] [Abstract][Full Text] [Related]
8. Preparation of [ Guleria M; Das T; Amirdhanayagam J; Sarma HD; Dash A Nucl Med Biol; 2019; 78-79():31-40. PubMed ID: 31731177 [TBL] [Abstract][Full Text] [Related]
9. The low-energy β(-) and electron emitter (161)Tb as an alternative to (177)Lu for targeted radionuclide therapy. Lehenberger S; Barkhausen C; Cohrs S; Fischer E; Grünberg J; Hohn A; Köster U; Schibli R; Türler A; Zhernosekov K Nucl Med Biol; 2011 Aug; 38(6):917-24. PubMed ID: 21843788 [TBL] [Abstract][Full Text] [Related]
10. Preparation of patient doses of (177)Lu-DOTA-TATE using indigenously produced (177)Lu: the Indian experience. Das T; Chakraborty S; Kallur KG; Venkatesh M; Banerjee S Cancer Biother Radiopharm; 2011 Jun; 26(3):395-400. PubMed ID: 21728843 [TBL] [Abstract][Full Text] [Related]
11. Consequences of meta-stable (177m)Lu admixture in (177)Lu for patient dosimetry. Konijnenberg MW Curr Radiopharm; 2015; 8(2):145-9. PubMed ID: 25771362 [TBL] [Abstract][Full Text] [Related]
13. Influence of cations on the complexation yield of DOTATATE with yttrium and lutetium: a perspective study for enhancing the 90Y and 177Lu labeling conditions. Asti M; Tegoni M; Farioli D; Iori M; Guidotti C; Cutler CS; Mayer P; Versari A; Salvo D Nucl Med Biol; 2012 May; 39(4):509-17. PubMed ID: 22172388 [TBL] [Abstract][Full Text] [Related]
14. Long-term results of PRRT in advanced bronchopulmonary carcinoid. Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198 [TBL] [Abstract][Full Text] [Related]
15. On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor. Das T; Chakraborty S; Banerjee S; Venkatesh M Appl Radiat Isot; 2007 Mar; 65(3):301-8. PubMed ID: 17110119 [TBL] [Abstract][Full Text] [Related]
16. Preparation of therapeutic dose of 177Lu-DOTA-TATE using a novel single vial freeze-dried kit: a comparison with 'in-situ' preparation at hospital radiopharmacy. Das T; Banerjee S; Shinto A; Kamaleshwaran KK; Sarma HD Curr Radiopharm; 2014; 7(1):12-9. PubMed ID: 24934713 [TBL] [Abstract][Full Text] [Related]
17. Estimation of specific activity of 177Lu by 'saturation assay' principle using DOTA as ligand. Pillai AM; Chakraborty S; Das T Curr Radiopharm; 2015; 8(2):123-8. PubMed ID: 25771375 [TBL] [Abstract][Full Text] [Related]
18. Development and validation of the HPLC method for quality control of radiolabelled DOTA-TATE and DOTA-TOC preparations. Radzik M; Pijarowska-Kruszyna J; Jaroń A; Maurin M; Decristoforo C; Mikołajczak R; Garnuszek P Nucl Med Biol; 2021 Feb; 93():63-73. PubMed ID: 33360498 [TBL] [Abstract][Full Text] [Related]
19. Salvage peptide receptor radionuclide therapy with [ van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116 [TBL] [Abstract][Full Text] [Related]
20. The radiometal makes a difference. Synthesis and preliminary characterisation of DOTA-minigastrin analogue complexes with Ga, Lu and Y. Maurin M; Garnuszek P; Baran P; Pawlak D; Mikołajczak R Nucl Med Rev Cent East Eur; 2015; 18(2):51-5. PubMed ID: 26315862 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]